$350M deal adds minimally invasive uterine fibroid treatment to Hologic’s offerings.
Hologic (Nasdaq: HOLX) has signed a definitive agreement to acquire Gynesonics, a leader in uterine fibroid treatment, for approximately $350 million.
Advancing Women’s Health with the Sonata System
Gynesonics’ Sonata System combines intrauterine ultrasound guidance with targeted radiofrequency ablation, enabling gynecologists to diagnose and treat uterine fibroids in a single, minimally invasive procedure.
“This acquisition furthers our commitment to providing women with minimally invasive treatment options,” said Brandon Schnittker, Division President of Surgical Solutions at Hologic.
Strategic Expansion of Surgical Offerings
The deal complements Hologic’s existing portfolio, enhancing its ability to offer gynecological surgeons a broader range of solutions for fibroid and heavy period management.
Hologic has been expanding through acquisitions, including its $310 million purchase of Endomagnetics in July, which added breast surgery localization and lymphatic tracing solutions to its offerings.
With this acquisition, Hologic continues to lead in innovation for women’s health, driving access to advanced, patient-centered solutions.
Follow MEDWIRE.AI for updates on MedTech innovations and strategic acquisitions.
